VEGF and VEGF-R Agonists and Antagonists Product description The present Competitive Intelligence Report about VEGF and VEGF-R agonists and antagonists provides a competitor evaluation in the field of VEGF and its receptor targeting molecules for treatment of cancer, AMD and for neuroprotection as of September 2009. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The importance of tumor angiogenesis in tumor biology is now widely accepted and has emerged as a valid therapeutic target in oncology. Vascular endothelial growth factor (VEGF) represents a key mediator of tumor-initiated angiogenesis and the first target of antiangiogenesis agents introduced in clinical practice. VEGF and VEGF receptor antagonists have revolutionized therapy of cancer which is reflected by their outstanding commercial success: 2008 sales of US$ 6.4 bln only in oncology. VEGF blockers found further use in inhibiting or even reversing angiogenesis in neovascular (wet) age-related macular degeneration (AMD). This market already reached US$ 1.8 bln in 2008.
Obviously, the total market size of US$ 8.2 bln for VEGF and VEGF receptor (VEGF-R) antagonists has attracted many companies to invest in follow-up and next generation molecules targeting VEGF and VEGF-R. The clinically validated target provides a low risk opportunity for new technologies with proteins, RNA, antibodies and vaccines for validation of the technologies. Multi-target receptor tyrosine kinase (RTK) inhibitors are another possibility to further increase the efficacy of VEGF-R antagonists by adding anti-proliferative or anti-migration effects. In contrast to antagonism of angiogenesis, the growth factor activity of VEGF has created a high level of interest for neuroprotection and several approaches are in clinical evaluation.
The report includes a compilation of current active projects in research and development of molecules targeting VEGF or VEGF receptor. In addition, the report lists company-specific R&D pipelines of VEGF/R targeting molecules. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Index
- 2008 Sales of VEGF/R Antagonists
- VEGF-R Agonists
- Cardiovascular Applications
- Neurological Applications
- VEGF and VEGF-R Antagonists in Ophthalmology
- VEGF and VEGF-R Antagonists in Oncology
- Avastin Pipeline
- Biologics as VEGF and VEGF-R Antagonists
- Small Molecules as VEGF RTK Inhibitors
- Sutent Pipeline
- Nexavar Pipeline
- Selective VEGF RTK Inhibitors
- Dual Target VEGF RTK Inhibitors
- Triple Target VEGF RTK Inhibitors
- Multi-Target VEGF RTK Inhibitors
- Overview on RTK Inhibion Profiles of VEGF-R Inhibitors
- Corporate VEGF and VEGF-R Agonists and Antagonists
- About La Merie
Corporate VEGF/R Agonist and Antagonist R&D Pipelines
- Accelera
- ACT Biotech
- Advenchen Laboratories
- Affitech
- Allergan
- Allostera Pharma
- Alnylam Pharmaceuticals
- Amgen
- Ark Therapeutics
- AstraZeneca
- Attenuon
- Aveo Pharmaceuticals
- Bayer Schering-Pharma
- Bio-Sidus
- Boehringer Ingelheim
- Bristol-Myers Squibb (BMS)
- Cephalon
- Chugai
- Circadian
- CSL
- Cyclacell Pharmaceuticals
- DxS
- Edwards Lifesciences
- Eisai
- Eli Lilly
- Epitomics
- Ethycal Oncology Sciences (EOS)
- Exelixis
- Eyetech
- Genentech
- GlaxoSmithKline (GSK)
- Jubilant Innovation
- Kringle Pharmaceuticals
- Methylgen
- Millennium
- Molecular Partner
- Nanogen Biopharmaceuticals
- Neovacs
- NeuroNova
- Neurotech
- Novartis
- Onyx Pharmaceuticals
- Opko
- OSI Pharmaceuticals
- Oxford BioMedica
- Pepscan Systems
- Pfizer
- Pieris
- PTC Therapeutics
- Regeneron Pharmaceuticals
- Roche
- Sangamo Biosciences
- Sanofi-aventis
- Schering
- SibTech
- Sirna Therapeutics
- Sopherion Therapeutics
- Symphony Evolution
- Takeda Pharmaceutical
- Targa Therapeutics
- Tekmira
- Telik
- Tigris Pharmaceuticals
- Toolgen
- Trophogen
- VasGene
- ZymoGenetics
About Competitor Analysis Series The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced. Competitor analysis reports can be purchased as individual products or obtained by subscribing to R&D Pipeline News. R&D Pipeline News is published weekly 50-times a year and each issue contains at least two competitor evaluations. Individual products from the Competitor Analysis Series and R&D Pipeline News are independently elaborated by analysts of La Merie Business Intelligence and distributed by PipelineReview.com.
|
